695836ff-c54b-47bf-8a29-5224811afa7e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.490
- E2F_TARGETS+0.460
- G2M_CHECKPOINT+0.440
- MYC_TARGETS_V2+0.420
- INFLAMMATORY_RESPONSE+0.410
- MYC_TARGETS_V1+0.380
- TNFA_SIGNALING_VIA_NFKB+0.340
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.400
- BILE_ACID_METABOLISM-0.280
- PROTEIN_SECRETION-0.280
- HEDGEHOG_SIGNALING-0.270
- ANGIOGENESIS-0.240
- APICAL_JUNCTION-0.240
- CHOLESTEROL_HOMEOSTASIS-0.210
- NOTCH_SIGNALING-0.210
- ESTROGEN_RESPONSE_LATE-0.190
- ANDROGEN_RESPONSE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c63f3f74-14fa-4a9e-9925-30b0f5da7dd9 | — | — | 0.887 |
| 2 | MNG921 | — | — | 0.885 |
| 3 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.867 |
| 4 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.859 |
| 5 | SRR12475104 | — | — | 0.856 |
| 6 | 301853fd-348d-4a99-9625-7da725023c1d | — | — | 0.855 |
| 7 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.847 |
| 8 | SRR6013581 | — | cohortA1 | 0.844 |
| 9 | SRR1313135 | — | C | 0.843 |
| 10 | SRR29022833 | — | D | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.050 | Remibrutinib | — uncovered |